The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Daiichi Sankyo
Retrospective cohort study to evaluate the efficacy and safety of T-DXd in HER2-positive unresectable advanced or recurrent gastric or gastroesophageal junction cancer: EN-DEAVOR study.
 
Koki Nakanishi
No Relationships to Disclose
 
Yasuhiro Kodera
Honoraria - Abbvie; Amgen; Bristol Myers Squibb; Chugai Pharma; Covidien; Daiichi Sankyo; Edwards Lifesciences; Lilly Japan; Miyarisan Pharmaceutical; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Daii Sankyo
Research Funding - abbott Japan (Inst); Abbvie (Inst); Bayer (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); TOA Pharmaceuticals (Inst); Tsumura & Co. (Inst)
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Akitaka Makiyama
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Lilly Japan
 
Hirotaka Konishi
No Relationships to Disclose
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer
Research Funding - Eisai (Inst)
 
Yukiya Narita
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Ono Pharmaceutical (Inst)
 
Naotoshi Sugimoto
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Solasia Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Keiko Minashi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); BeiGene (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Motohiro Imano
No Relationships to Disclose
 
Rin Inamoto
No Relationships to Disclose
 
Hiroki Kume
No Relationships to Disclose
 
Keita Yamaguchi
Employment - Daiichi Sankyo
 
Wataru Hashimoto
No Relationships to Disclose
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Solasia Pharma
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)